SCHEMBL7250093

SCHEMBL7250093

CN(C)CCN(C(=O)Cc1c[nH]c2ccc(Br)cc12)C(C(=O)NC1CCCCC1)c1ccccc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.45
SOS1 Q07889 1/20 0.43
SLC6A4 P31645 1/20 0.39
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
MC4R P32245 1/20 0.38
MC5R P33032 1/20 0.38
MC3R P41968 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
UTS2R Q9UKP6 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7256847 0.92 MC4R (0.43) LMNAHTTNCOA1NCOA3MC4R
SCHEMBL9943348 0.76 HPGD (0.46) SOS1HTTMC4RMC5RMC3R
SCHEMBL9943291 0.75 SOS1 (0.45) SOS1HTTMC4RMC5RMC3R
SCHEMBL9943298 0.75 SOS1 (0.45) SOS1HTTMC4RMC5RMC3R
SCHEMBL9943285 0.73 SLC6A4 (0.44) SIGMAR1SLC6A4LMNABCHEACHE
SCHEMBL7251520 0.71 KMT2A (0.46) LMNAHTTMC4RMC5RMC3R
SCHEMBL17956951 0.69 NPSR1 (0.52) SIGMAR1SOS1LMNAHTTMC4R
SCHEMBL7251407 0.69 HPGD (0.46) HTTMC4RMC5RMC3RBCHE
SCHEMBL9943392 0.69 HPGD (0.47) SOS1HTTMC4RMC5RMC3R
SCHEMBL9943325 0.68 HPGD (0.44) SOS1HTTMC4RMC5RMC3R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030195212-A1 Novel melanocortin receptor agonists and antagonists MELACURE THERAPEUTICS AB (SE) 2003-10-16 US claimed
EP-1254114-A2 MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS Melacure Therapeutics AB (SE) 2002-11-06 EP claimed
WO-2001055106-A2 NOVEL MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS MELACURE THERAPEUTICS AB (SE) 2001-08-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195212-A1 Novel melanocortin receptor agonists and antagonists MC1R, MC5R, MC4R SIGMAR1 328/4885SOS1 4176/4885SLC6A4 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.